Biotech Values

[DewDiligence]

Yes, I bought an FMI “starter” position today. I was impressed by yesterday's BofA presentation (even though Brad Loncar called it lame on Twitter, with respect to the reimbursement issue). I couldn’t find any reason for the recent sell-off other than what I posted in #msg-101712486, so I decided it was time to pull the trigger.

As far as I can tell, FMI is one of few biotech companies that can truly be said to be sui generis. They seem to be at a good stage for investing; i.e. they’re a play on the future—but not the distant future—of mainstream cancer treatment.